Htuna, Talk to me about Dr Suzanne Kafaja, Assistant Clinical...

Htuna,
​

Talk to me about Dr Suzanne Kafaja, Assistant Clinical Professor in the Division of Rheumatology, Department of Medicine, at the University of California at Los Angeles (UCLA)...

Dr Kafaja has ALL the attributes of a real scientist which specialization in RA... ....
.... Unlike the many counterfeit , pretend scientists out there.


MESOBLAST RHEUMATOID ARTHRITIS TRIAL RESULTS PRESENTED AT EULAR ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY
New York, USA; and Melbourne, Australia; June 22, 2017: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) announced that results from the randomized, placebo-controlled 48-patient Phase 2 trial of its proprietary allogeneic Mesenchymal Precursor Cells (MPCs) in patients with biologic refractory rheumatoid arthritis (RA) were presented at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology held in Madrid June 14-17. The abstract was selected by peer review and presented by the trial’s independent investigators.

The EULAR Congress is the key European platform for showcasing innovation in rheumatology and highlighting the latest advances in the field. The 2017 Congress was attended by approximately 14,000 delegates from more than 120 countries.
Trial investigator, Dr Suzanne Kafaja, Assistant Clinical Professor in the Division of Rheumatology, Department of Medicine, at the University of California at Los Angeles (UCLA), presented both safety and efficacy outcomes of the trial using pre-specified analyses over the 12-week primary evaluation period, as well as follow-up results over 39 weeks.

Dr Kafaja said the trial had met its primary endpoints and the data indicated an early trend to improvements in patient-related outcome measures. "Taken together, these results show promise and support further development of Mesoblast's mesenchymal precursor cells for biologic-refractory rheumatoid arthritis patients, a population with substantial remaining medical need," she said​